SNMMI

ASNC, IAEA, SNMMI Update COVID-19 Best Practices for Nuclear Cardiology Labs
May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a flexible approach about which testing…
Top 10: Most Read Radiology Technology Content in March 2022
Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of March. This data was drawn from itnonline.com’s 149,000 viewers over the course of the month.
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment
March 23, 2022 — With today’s U.S.
Molecular Imaging Uncovers Effects of COVID-19 on the Brain
March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research summarized by…
SNMMI Task Force Reports Possible Effect of Omicron Infection on FDG PET/CT Scans
January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan.

New Information Statement Addresses How Labs Should Manage Evolving Issues as Pandemic Shifts Toward Chronic Endemic State

ASNC, IAEA, SNMMI Update COVID-19 Best Practices for Nuclear Cardiology Labs

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

May 04, 2022

News | Nuclear Imaging

New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

April 13, 2022

Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.

News | PET-CT

New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

April 11, 2022

Serial non-contrast axial chest CTs of three study participants with prior COVID-19 pneumonia.

Feature | Radiology Business | By Melinda Taschetta-Millane

Top 10: Most Read Radiology Technology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

March 31, 2022

With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.

News | Prostate Cancer

SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

March 23, 2022

F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.

News | Coronavirus (COVID-19)

Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

March 23, 2022

Dose tracking software allows hospitals and imaging centers to track levels of radiation used by exam type protocol.

Feature | Radiation Dose Management | By Melinda Taschetta-Millane

Measuring Radiation Dose

Dose tracking software allows hospitals and imaging centers to track levels of radiation used by exam type protocol. It ...

March 22, 2022

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.

News | SNMMI

SNMMI designates first Radiopharmaceutical Therapy Centers of Excellence

March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the ...

March 16, 2022

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.

News | Nuclear Imaging

Position Statement from SNMMI Regarding Situation in Ukraine

March 3, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine ...

March 03, 2022

The Task Force members have recently observed an unusual imaging pattern on FDG PET/CT or FDG PET/MR that may be due to COVID-19 infection.

News | Coronavirus (COVID-19)

SNMMI Task Force Reports Possible Effect of Omicron Infection on FDG PET/CT Scans

January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan. 14 regarding ...

January 17, 2022

Case examples of quantitative plaque analysis on coronary CT angiography and 18F-NaF PET in patients with established coronary artery disease. Hybrid CT angiography and 18F-NaF PET of coronary arteries. (A) A 70-y-old male, who presented with diffused largely noncalcified disease (middle panel in red) in the LAD and demonstrated increased 18F-NaF uptake in the LAD on PET. (B) A 59-y-old male with mild LCX atherosclerosis, who presented with a high noncalcified plaque burden (middle panel in red) on CT angio

News | PET-CT

PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack

January 12, 2022 — By combining information from two advanced imaging techniques with clinical data, physicians can ...

January 12, 2022

18F-FDG PET in patients with long-COVID syndrome. A and B: Transaxial sections of group averaged, spatially normalized 18F-FDG PET scans in patients with long-COVID syndrome (A) and control patients (B). C: The pattern expression score (PES; *adjusted for age and sex, for illustration purposes) of the previously established COVID-19-related spatial covariance pattern was not significantly different between patients with long-COVID syndrome and control patients. Boxplots (grey), as well as individual values

News | Coronavirus (COVID-19)

Molecular Imaging Suggests Long-COVID Symptoms may be Caused by Fatigue

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

November 01, 2021

Determination of ER status of disease. In 59-y-old woman diagnosed with ER-positive lobular BC 2 y previously and treated with tamoxifen, ER-positive bone metastases were identified 1 y after initial diagnosis.

News | Breast Imaging

Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients

October 4, 2021 — A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for ...

October 04, 2021

Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond

Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

5 Strategies for Improving Your Nuclear Radiology Lab

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

September 16, 2021

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).

News | Nuclear Imaging

Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

August 04, 2021

A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.

News | PET Imaging

Total-body PET Imaging Exceeds Industry Standards

July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high ...

July 10, 2021

The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

News | PET Imaging

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

June 28, 2021

GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.

News | Nuclear Imaging

GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

June 22, 2021

A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

News | Prostate Cancer

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

June 21, 2021

A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

News | PET Imaging

New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

June 16, 2021